Washington, DC – October 2, 2015 – Cooley advised Scioderm on its sale to Amicus Therapeutics. According to the terms of the transaction, Amicus will pay $229 million in stock and cash along with up to $618 million upon achievement of regulatory and sales milestones and $100 million for a priority review voucher.
Scioderm is a privately held, clinical-stage biopharmaceutical company focused on developing innovative therapies to address diseases with high unmet need, including rare diseases. Amicus Therapeutics is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases.
The M&A team advising Scioderm included partner and head of Cooley's M&A practice, Barbara Borden, partner Christian Plaza, and associates Marc Samuel, Eric Dixon, Alison McCormick and Kerry Killeen.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.